ClinicalTrials.gg
RecruitingNCT07852338AB BIOH - DFUUpdated Oct 16, 2026

a Prospective, Multicenter, Randomized Controlled Trial, With a Non-randomized Sentinel Cohort, Evaluating the Efficacy of Bioxheal, a Single-layer Placental-derived Biologic in Nonhealing Diabetic Foot Ulcers

A Phase 3 interventional study of Standard of Care and BIOxHEAL (human amniotic membrane allograft) in Diabetic Foot Ulcer, Amniotic Membrane Placental Allograft and Biologic, sponsored by Applied Biologics, LLC. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-16.

Sponsored by Applied Biologics, LLC · Phase 3, Interventional, and Treatment

How we know

Updated Oct 16, 2026Primary completion movedStudy completion moved+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
253
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 381 studies in Diabetic Foot with a site in United States — 66 open to participants now, 84 under way, 3 of them phase 3. Diabetic Foot · United States.

Planned enrollment
34th of 322
253 · median 60
Started
2026
with 13 others
Phase 3
32 of 381
3 open now
Primary completion
2027-09
later than 68 of 83 live
Registered
381st of 381
by date

Among the 381 studies in Diabetic Foot with a site in United States, this one is the 34th largest by planned enrollment of the 322 interventional ones that give a count, is one of 14 that started in 2026, is one of 32 in phase 3, reaches primary completion later than 68 of the 83 other live ones, and was the 381st registered.

Diabetic Foot

1,079 studies on the registry are indexed under Diabetic Foot; 221 are open to participants now.

Browse Diabetic Foot studies →

Open to participants now

66 of the 381 studies in Diabetic Foot with a site in United States are open now. Recruiting first, the newest first:

60 more — sign in →

All 66 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 139 Diabetic Foot studies recruiting now, 98 (71%) set no upper age limit and 12 (9%) stop at 75 or younger; 5 take children under 18; 11 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 381 studies in Diabetic Foot with a site in United States, or all of them as a file.
02

Study summary

BIOxHEAL is an investigational placental-derived biologic being evaluated for the treatment of nonhealing diabetic foot ulcers. Adults with type 1 or type 2 diabetes who have a diabetic foot ulcer that has not healed with standard wound care may be eligible to participate. Participants in the randomized phase are assigned by chance in a 2:1 ratio to receive either BIOxHEAL administered topically in combination with standard of care (SOC), or SOC alone. Treatment is administered once weekly for up to 12 weeks or until complete ulcer closure. The primary objective is to evaluate whether BIOxHEAL plus SOC increases the proportion of target ulcers achieving complete closure at Week 12 compared with SOC alone.

Read the detailed description

Phase 3, multicenter, prospective, open-label, randomized controlled study conducted at up to 30 U.S. clinical centers. A non-randomized sentinel cohort (5 completed participants required, with up to 10 participants enrolled) will first receive BIOxHEAL plus SOC to assess early safety. Following DSMB review and FDA authorization to proceed, 243 participants will be randomized 2:1 to BIOxHEAL plus SOC or SOC alone, with randomization stratified by baseline ulcer area and ulcer duration. BIOxHEAL is administered topically once weekly for up to 12 weeks or until complete ulcer closure. Complete closure is confirmed approximately 2 weeks later. Participants are subsequently followed for 3 months.

03

Conditions studied

  • Diabetic Foot Ulcer
  • Amniotic Membrane Placental Allograft
  • Biologic

Browse trials for

Keywords

  • Diabetic Foot Ulcer
  • Chronic Wound Wound Healing
04

Who can participate

The criteria were revised on the registry on Oct 16, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Participants must be at least 18 years of age or older. Participants must have a diagnosis of type 1 or 2 diabetes mellitus. At randomization (or enrollment for the sentinel cohort), participants must have a target ulcer with a minimum surface area of 1.0 cm2 and a maximum surface area of 25.0 cm2 measured post debridement.

The target ulcer must have been present for a minimum of 4 weeks and a maximum of 52 weeks of standard of care prior to the initial screening visit.

The target ulcer must be located on the foot with at least 50% of the ulcer below the malleolus.

The target ulcer must be Wagner Grade 1 extending at least through the dermis or subcutaneous tissue.

The affected limb must have adequate perfusion confirmed by vascular assessment. Any of the following methods performed within 3 months of the first screening visit are acceptable:

ABI greater than or equal to 0.7 and less than or equal to 1.3 TBI greater than or equal to 0.6 TCOM greater than or equal to 40 mmHg Arterial Doppler ultrasound with biphasic dorsalis pedis and posterior tibial vessels at the level of the ankle on the extremity where the index ulcer is located If the participant has two or more ulcers, they must be separated by at least 2 cm. The largest ulcer satisfying the inclusion and exclusion criteria will be designated as the target ulcer.

The participant must consent to using the prescribed offloading method for the duration of the study.

The participant must agree to attend the weekly study visits required by the protocol.

The participant must be willing and able to participate in the process.

The participant must have a suitable living environment to manage prescribed offloading and wound care management.

Exclusion criteria

Exclusion Criteria:

Known of less than 6 months. Target ulcer is not secondary to diabetes. Wagner Grade 2 to 5 ulcers. Target ulcer is infected, or there is cellulitis in the surrounding skin.

Evidence of osteomyelitis complicating the target ulcer, based on clinical assessment supported by at least one of the following:

Imaging (for example, plain radiography, MRI, or nuclear medicine study) consistent with osteomyelitis Positive bone culture Abnormal inflammatory markers (for example, ESR, CRP) in conjunction with clinical signs highly suggestive of osteomyelitis per Investigator judgment - Documentation of the basis for diagnosing or excluding osteomyelitis must be available in the participant's source documents Infection in the target ulcer or in a remote location that requires systemic antibiotic therapy.

Receiving (including systemic at doses greater than 10 mg of prednisone per day or equivalent) or cytotoxic chemotherapy.

Topical application of steroids to the ulcer surface within one month of initial screening.

Previous partial amputation on the affected foot, if the resulting deformity impedes proper offloading of the target ulcer.

(HbA1c) greater than or equal to 12% within 3 months of the initial screening visit.

The surface area of the target ulcer has reduced in size by more than 40% between Screening Visit 1 and Treatment Visit 1 during the protocol-defined screening period.

Acute Charcot foot, or an inactive Charcot foot, that impedes proper offloading of the target ulcer.

Women who are pregnant or considering becoming pregnant within the next 6 months.

Male or female participants who are unwilling or unable to comply with the required measures for the duration of study participation.

End stage renal disease requiring dialysis. Serum creatinine level greater than 3.0 mg/dL. (AST, GOT) and/or alanine aminotransferase (ALT, GPT) greater than 3 times the .

A medical or psychological condition that, in the opinion of the investigator, may interfere with study assessments.

Treated with hyperbaric oxygen therapy or a Cellular and/or Tissue Product (CTP) in the 30 days prior to the initial screening visit.

Mini Nutritional Assessment (MNA) screening score below 12.

Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
253 participants (estimated)

Study arms

  • Experimental
    Sentinel Cohort: BIOxHEAL + SOC

    Non-randomized sentinel cohort (5 completed participants required, up to 10 enrolled). Participants receive BIOxHEAL administered topically once weekly plus SOC for up to 12 weeks or until complete ulcer closure, to assess early safety before the randomized phase.

    Other: Standard of Care · Biological: BIOxHEAL (human amniotic membrane allograft)

  • Active comparator
    Randomized: SOC Alone

    Participants randomized 2:1 to receive protocol-defined SOC alone, with weekly treatment visits for up to 12 weeks or until complete ulcer closure, with closure confirmed approximately 2 weeks later.

    Other: Standard of Care

  • Experimental
    Randomized: BIOxHEAL + SOC

    Participants randomized 2:1 to receive BIOxHEAL administered topically once weekly plus SOC for up to 12 weeks or until complete ulcer closure, with closure confirmed approximately 2 weeks later.

    Biological: BIOxHEAL (human amniotic membrane allograft)

Interventions

  • OtherStandard of Care

    Protocol-defined standard of care (SOC) for diabetic foot ulcers, performed at each study visit: wound cleansing with sterile saline, sharp debridement as clinically indicated, a non-adherent silicone primary dressing with an absorbent secondary dressing to maintain a moist wound environment, offloading for plantar and pressure-bearing ulcers (Foot Defender boot, Total Contact Cast, or Medical Monitor-approved equivalent), and diabetes education and nutritional support, including smoking cessation counseling for current smokers.

  • BiologicalBIOxHEAL (human amniotic membrane allograft)

    BIOxHEAL is an investigational, sterile, single-use biologic derived from human amniotic membrane. BIOxHEAL is administered topically to the target ulcer once weekly in combination with protocol-defined standard of care for up to 12 weeks or until complete ulcer closure. Each unit is individually packaged for single-patient, one-time use.

06

What researchers measure

Primary outcomes

  1. Proportion of target ulcers with complete wound closure at Week 12

    Complete closure is defined as 100% epithelialization, assessed by the Investigator and confirmed by blinded, independent wound evaluators. Compared between BIOxHEAL plus standard of care and standard of care alone.

    Time frame: Baseline to Week 12

Secondary outcomes

  1. Proportion of target ulcers with complete wound closure at Week 8

    Complete closure is defined as 100% epithelialization, assessed by the Investigator and confirmed by blinded, independent wound evaluators. Compared between BIOxHEAL plus standard of care and standard of care alone.

    Time frame: Baseline to Week 8.

  2. Proportion of participants with treatment-emergent adverse events (TEAEs), serious adverse events (SAEs) and adverse events of special interest (AESIs)

    Number and proportion of participants with TEAEs, including SAEs and AESIs. Compared between BIOxHEAL plus standard of care and standard of care alone.

    Time frame: From first treatment through the end of follow-up (at least 3 months after complete wound healing, or after Visit 13 if not healed), assessed up to approximately 6 months

  3. Mean change in Wound Quality-of-Life (wQOL) score from baseline to Week 12

    Change in wQOL questionnaire score. Compared between BIOxHEAL plus standard of care and standard of care alone.

    Time frame: Baseline to 12 weeks

  4. Proportion of participants with major and minor lower extremity amputations, and number and frequency of amputations

    Number and frequency of major and minor lower extremity amputations occurring during the study period.

    Time frame: From first treatment through the end of the follow-up period, assessed up to approximately 6 months

  5. Proportion of participants with completely closed diabetic foot ulcers at any time during the study

    Complete closure is defined as 100% epithelialization, assessed by the Investigator and confirmed by blinded, independent wound evaluators. Compared between BIOxHEAL plus standard of care and standard of care alone.

    Time frame: From first treatment until complete wound closure (100% epithelialization) is first confirmed, assessed up to approximately 6 months

Other outcomes

  1. Number of sentinel cohort participants with treatment-emergent adverse events (TEAEs), serious adverse events (SAEs) and adverse events of special interest (AESIs) during the treatment period

    Early safety assessment in the non-randomized sentinel cohort, in which all participants receive BIOxHEAL plus standard of care. Safety data from the first 5 participants who complete the treatment period are reviewed by the DSMB and the FDA before randomization begins. The DSMB monitors for risks associated with tissue-based products, including localized inflammatory responses, graft rejection, or unexpected infections.

    Time frame: From first treatment through the end of the treatment period (up to 12 weeks)

07

Study locations

1 of 1 sites recruiting
  • NOMS Ankle and Foot Care Center
    Boardman, Ohio 44512, United States
    Recruiting
08

References and documents

Individual participant data

Plan to share: No — There is currently no plan to make individual participant data (IPD) available to other researchers. The Sponsor will consider reasonable requests for de-identified data after completion of the study and regulatory review, subject to participant privacy protections and applicable agreements.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Oct 2026; primary completion for Sep 2027, 11 months later.

Of 18 phase 3 interventional studies under Diabetic Foot, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 64. This study's planned 11 months is below that.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 16, 2026: primary completion Nov 2028 → Sep 2027 and completion Jan 2029 → Sep 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Sep 25, 2026
First posted
Oct 1, 2026
StartEst.
Oct 8, 2026
Primary completionEst.
Sep 2027was Nov 2028
CompletionEst.
Sep 2027was Jan 2029
Last update
Oct 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Nov 2028→Sep 2027
Oct 16, 2026
Study completion
Jan 2029→Sep 2027
Oct 16, 2026
Eligibility
6 inclusion criteria edited, 4 added, 8 removed; 10 exclusion criteria edited, 5 added, 11 removed
What changed in the criteria
Inclusion criteria
  • RemovedAge 18 years or older
  • RemovedDiagnosis of type 1 or type 2 diabetes mellitus
  • RemovedAt randomization, a target ulcer with a surface area of 1.0 cm² to 25.0 cm², measured after debridement
  • AddedParticipants must be at least 18 years of age or older. Participants must have a diagnosis of type 1 or 2 diabetes mellitus. At randomization (or enrollment for the sentinel cohort), participants must have a target ulcer with a minimum surface area of 1.0 cm2 and a maximum surface area of 25.0 cm2 measured post debridement.
  • EditedTargetThe target ulcer must have been present for at leasta minimum of 4 weeks and no more thana maximum of 52 weeks of standard of care beforeprior to the firstinitial screening visit.
  • EditedTargetThe target ulcer must be located on the foot, with at least 50% of the ulcer below the malleolus.
  • EditedTargetThe target ulcer ismust be Wagner gradeGrade 1, extending at least through the dermis or subcutaneous tissue.
  • RemovedAdequate blood flow to the affected limb, confirmed within 3 months of the first screening visit by any one of the following:
  • RemovedAnkle-brachial index (ABI) of 0.7 to 1.3
  • RemovedToe-brachial index (TBI) of 0.6 or higher * Transcutaneous oxygen measurement (TcPO2) of 40 mmHg or higher
  • RemovedArterial Doppler ultrasound showing biphasic dorsalis pedis and posterior tibial flow at the ankle of the affected limb
  • RemovedIf two or more ulcers are present, they are at least 2 cm apart (the largest eligible ulcer is the target ulcer)
  • AddedThe affected limb must have adequate perfusion confirmed by vascular assessment. Any of the following methods performed within 3 months of the first screening visit are acceptable:
  • AddedABI greater than or equal to 0.7 and less than or equal to 1.3 TBI greater than or equal to 0.6 TCOM greater than or equal to 40 mmHg Arterial Doppler ultrasound with biphasic dorsalis pedis and posterior tibial vessels at the level of the ankle on the extremity where the index ulcer is located If the participant has two or more ulcers, they must be separated by at least 2 cm. The largest ulcer satisfying the inclusion and exclusion criteria will be designated as the target ulcer.
  • EditedAgreesThe participant must consent to useusing the prescribed offloading method for the wholeduration of the study.
  • EditedAgreesThe participant must agree to attend the weekly study visits required by the protocol.
  • EditedWillingThe participant must be willing and able to take partparticipate in the informed consent process.
  • AddedThe participant must have a suitable living environment to manage prescribed offloading and wound care management.
Exclusion criteria
  • RemovedLife expectancy of less than 6 months
  • RemovedTarget ulcer not caused by diabetes
  • RemovedInfected target ulcer, or cellulitis of the surrounding skin
  • AddedKnown life expectancy of less than 6 months. Target ulcer is not secondary to diabetes. Wagner Grade 2 to 5 ulcers. Target ulcer is infected, or there is cellulitis in the surrounding skin.
  • EditedOsteomyelitisEvidence of osteomyelitis complicating the target ulcer, based on clinical assessment supported by at least one of the following:
  • RemovedImaging consistent with osteomyelitis (e.g., X-ray, MRI or nuclear medicine study)
  • RemovedPositive bone culture
  • RemovedAbnormal inflammatory markers (e.g., ESR, CRP) with clinical signs highly suggestive of osteomyelitis, in the Investigator's judgment
  • RemovedInfection of the target ulcer or elsewhere that requires systemic antibiotics
  • AddedImaging (for example, plain radiography, MRI, or nuclear medicine study) consistent with osteomyelitis Positive bone culture Abnormal inflammatory markers (for example, ESR, CRP) in conjunction with clinical signs highly suggestive of osteomyelitis per Investigator judgment - Documentation of the basis for diagnosing or excluding osteomyelitis must be available in the participant's source documents Infection in the target ulcer or in a remote location that requires systemic antibiotic therapy.
  • EditedCurrent use ofReceiving immunosuppressants (including systemic corticosteroids aboveat doses greater than 10 mg of prednisone per day or equivalent) or cytotoxic chemotherapy.
  • EditedTopical application of steroids applied to the ulcer surface within 1one month before the firstof initial screening visit.
  • EditedPrevious partial amputation ofon the affected foot, if the resulting deformity preventsimpedes proper offloading of the target ulcer.
  • EditedGlycated hemoglobin (HbA1c of) greater than or equal to 12% or higher within 3 months beforeof the firstinitial screening visit.
  • RemovedTarget ulcer area decreased by more than 20% in the 2 weeks before the first screening visit
  • RemovedTarget ulcer area decreases by 25% or more during the screening period on standard of care (from the first screening visit to the randomization visit)
  • AddedThe surface area of the target ulcer has reduced in size by more than 40% between Screening Visit 1 and Treatment Visit 1 during the protocol-defined screening period.
  • EditedAcute Charcot foot, or an inactive Charcot foot, that preventsimpedes proper offloading of the target ulcer.
  • EditedPregnant,Women who are pregnant or planning to becomeconsidering becoming pregnant within the next 6 months.
  • RemovedUnwilling or unable to use the required contraception during the study
  • RemovedEnd-stage renal disease requiring dialysis
  • AddedMale or female participants who are unwilling or unable to comply with the required contraceptive measures for the duration of study participation.

…and 4 more changes, on the record history on ClinicalTrials.gov ↗

Oct 16, 2026
Interventions
Added Standard of Care·Biological: BIOxHEAL (human amniotic membrane allograft); removed Biological: All sentinel cohort participants will receive biologic plus SOC. who receive at least one treatment of the biologic plus SOC and complete the treatment period of 12 weeks.·Standard wound care for diabetic foot ulcers·Biological: Participants in the randomized phase are assigned by randomization (2:1) to BIOxHEAL plus SOC or SOC alone. once weekly for up to 12 weeks or until complete ulcer closure
Oct 16, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • EditedPrimary Endpoint - Proportion of Target Ulcerstarget ulcers with Complete Closurecomplete wound closure at Week 12Time frame: Baseline to Week 12
Oct 16, 2026
Secondary outcomes
2 edited, 4 added, 2 removed
What changed in the outcomes
  • EditedProportion of Participants With Complete Closure of the Target Ulcertarget ulcers with complete wound closure at Week 8Time frame: Baseline Week 8. → Baseline to Week 8.
  • EditedMean Percent Changechange in Target Ulcer Surface Area From BaselineWound Quality-of-Life (wQOL) score from baseline to Week 12Time frame: Baseline to Week 12 → Baseline to 12 weeks
  • AddedProportion of participants with treatment-emergent adverse events (TEAEs), serious adverse events (SAEs) and adverse events of special interest (AESIs)Time frame: From first treatment through the end of follow-up (at least 3 months after complete wound healing, or after Visit 13 if not healed), assessed up to approximately 6 months
  • AddedProportion of participants with major and minor lower extremity amputations, and number and frequency of amputationsTime frame: From first treatment through the end of the follow-up period, assessed up to approximately 6 months
  • AddedProportion of participants with completely closed diabetic foot ulcers at any time during the studyTime frame: From first treatment until complete wound closure (100% epithelialization) is first confirmed, assessed up to approximately 6 months
  • RemovedMean Change in Wound-QoL-17 Global Score From Baseline to Week 12Time frame: Baseline to week 12
  • RemovedParticipants With Major or Minor Lower Extremity AmputationTime frame: Baseline through end of follow-up (approximately Week 24)
  • Addedother outcomeNumber of sentinel cohort participants with treatment-emergent adverse events (TEAEs), serious adverse events (SAEs) and adverse events of special interest (AESIs) during the treatment periodTime frame: From first treatment through the end of the treatment period (up to 12 weeks)
Oct 16, 2026
Registered
First appeared on the registry
Oct 1, 2026
Show all 2 updates
  1. Oct 16, 2026
    Primary completion Nov 2028→Sep 2027
    Study completion Jan 2029→Sep 2027
    Eligibility 6 inclusion criteria edited, 4 added, 8 removed; 10 exclusion criteria edited, 5 added, 11 removed
    What changed in the criteria
    Inclusion criteria
    • RemovedAge 18 years or older
    • RemovedDiagnosis of type 1 or type 2 diabetes mellitus
    • RemovedAt randomization, a target ulcer with a surface area of 1.0 cm² to 25.0 cm², measured after debridement
    • AddedParticipants must be at least 18 years of age or older. Participants must have a diagnosis of type 1 or 2 diabetes mellitus. At randomization (or enrollment for the sentinel cohort), participants must have a target ulcer with a minimum surface area of 1.0 cm2 and a maximum surface area of 25.0 cm2 measured post debridement.
    • EditedTargetThe target ulcer must have been present for at leasta minimum of 4 weeks and no more thana maximum of 52 weeks of standard of care beforeprior to the firstinitial screening visit.
    • EditedTargetThe target ulcer must be located on the foot, with at least 50% of the ulcer below the malleolus.
    • EditedTargetThe target ulcer ismust be Wagner gradeGrade 1, extending at least through the dermis or subcutaneous tissue.
    • RemovedAdequate blood flow to the affected limb, confirmed within 3 months of the first screening visit by any one of the following:
    • RemovedAnkle-brachial index (ABI) of 0.7 to 1.3
    • RemovedToe-brachial index (TBI) of 0.6 or higher * Transcutaneous oxygen measurement (TcPO2) of 40 mmHg or higher
    • RemovedArterial Doppler ultrasound showing biphasic dorsalis pedis and posterior tibial flow at the ankle of the affected limb
    • RemovedIf two or more ulcers are present, they are at least 2 cm apart (the largest eligible ulcer is the target ulcer)
    • AddedThe affected limb must have adequate perfusion confirmed by vascular assessment. Any of the following methods performed within 3 months of the first screening visit are acceptable:
    • AddedABI greater than or equal to 0.7 and less than or equal to 1.3 TBI greater than or equal to 0.6 TCOM greater than or equal to 40 mmHg Arterial Doppler ultrasound with biphasic dorsalis pedis and posterior tibial vessels at the level of the ankle on the extremity where the index ulcer is located If the participant has two or more ulcers, they must be separated by at least 2 cm. The largest ulcer satisfying the inclusion and exclusion criteria will be designated as the target ulcer.
    • EditedAgreesThe participant must consent to useusing the prescribed offloading method for the wholeduration of the study.
    • EditedAgreesThe participant must agree to attend the weekly study visits required by the protocol.
    • EditedWillingThe participant must be willing and able to take partparticipate in the informed consent process.
    • AddedThe participant must have a suitable living environment to manage prescribed offloading and wound care management.
    Exclusion criteria
    • RemovedLife expectancy of less than 6 months
    • RemovedTarget ulcer not caused by diabetes
    • RemovedInfected target ulcer, or cellulitis of the surrounding skin
    • AddedKnown life expectancy of less than 6 months. Target ulcer is not secondary to diabetes. Wagner Grade 2 to 5 ulcers. Target ulcer is infected, or there is cellulitis in the surrounding skin.
    • EditedOsteomyelitisEvidence of osteomyelitis complicating the target ulcer, based on clinical assessment supported by at least one of the following:
    • RemovedImaging consistent with osteomyelitis (e.g., X-ray, MRI or nuclear medicine study)
    • RemovedPositive bone culture
    • RemovedAbnormal inflammatory markers (e.g., ESR, CRP) with clinical signs highly suggestive of osteomyelitis, in the Investigator's judgment
    • RemovedInfection of the target ulcer or elsewhere that requires systemic antibiotics
    • AddedImaging (for example, plain radiography, MRI, or nuclear medicine study) consistent with osteomyelitis Positive bone culture Abnormal inflammatory markers (for example, ESR, CRP) in conjunction with clinical signs highly suggestive of osteomyelitis per Investigator judgment - Documentation of the basis for diagnosing or excluding osteomyelitis must be available in the participant's source documents Infection in the target ulcer or in a remote location that requires systemic antibiotic therapy.
    • EditedCurrent use ofReceiving immunosuppressants (including systemic corticosteroids aboveat doses greater than 10 mg of prednisone per day or equivalent) or cytotoxic chemotherapy.
    • EditedTopical application of steroids applied to the ulcer surface within 1one month before the firstof initial screening visit.
    • EditedPrevious partial amputation ofon the affected foot, if the resulting deformity preventsimpedes proper offloading of the target ulcer.
    • EditedGlycated hemoglobin (HbA1c of) greater than or equal to 12% or higher within 3 months beforeof the firstinitial screening visit.
    • RemovedTarget ulcer area decreased by more than 20% in the 2 weeks before the first screening visit
    • RemovedTarget ulcer area decreases by 25% or more during the screening period on standard of care (from the first screening visit to the randomization visit)
    • AddedThe surface area of the target ulcer has reduced in size by more than 40% between Screening Visit 1 and Treatment Visit 1 during the protocol-defined screening period.
    • EditedAcute Charcot foot, or an inactive Charcot foot, that preventsimpedes proper offloading of the target ulcer.
    • EditedPregnant,Women who are pregnant or planning to becomeconsidering becoming pregnant within the next 6 months.
    • RemovedUnwilling or unable to use the required contraception during the study
    • RemovedEnd-stage renal disease requiring dialysis
    • AddedMale or female participants who are unwilling or unable to comply with the required contraceptive measures for the duration of study participation.

    …and 4 more changes, on the record history on ClinicalTrials.gov ↗

    Primary outcomes 1 edited
    What changed in the outcomes
    • EditedPrimary Endpoint - Proportion of Target Ulcerstarget ulcers with Complete Closurecomplete wound closure at Week 12Time frame: Baseline to Week 12
    Secondary outcomes 2 edited, 4 added, 2 removed
    What changed in the outcomes
    • EditedProportion of Participants With Complete Closure of the Target Ulcertarget ulcers with complete wound closure at Week 8Time frame: Baseline Week 8. → Baseline to Week 8.
    • EditedMean Percent Changechange in Target Ulcer Surface Area From BaselineWound Quality-of-Life (wQOL) score from baseline to Week 12Time frame: Baseline to Week 12 → Baseline to 12 weeks
    • AddedProportion of participants with treatment-emergent adverse events (TEAEs), serious adverse events (SAEs) and adverse events of special interest (AESIs)Time frame: From first treatment through the end of follow-up (at least 3 months after complete wound healing, or after Visit 13 if not healed), assessed up to approximately 6 months
    • AddedProportion of participants with major and minor lower extremity amputations, and number and frequency of amputationsTime frame: From first treatment through the end of the follow-up period, assessed up to approximately 6 months
    • AddedProportion of participants with completely closed diabetic foot ulcers at any time during the studyTime frame: From first treatment until complete wound closure (100% epithelialization) is first confirmed, assessed up to approximately 6 months
    • RemovedMean Change in Wound-QoL-17 Global Score From Baseline to Week 12Time frame: Baseline to week 12
    • RemovedParticipants With Major or Minor Lower Extremity AmputationTime frame: Baseline through end of follow-up (approximately Week 24)
    • Addedother outcomeNumber of sentinel cohort participants with treatment-emergent adverse events (TEAEs), serious adverse events (SAEs) and adverse events of special interest (AESIs) during the treatment periodTime frame: From first treatment through the end of the treatment period (up to 12 weeks)
    Interventions Added Standard of Care·Biological: BIOxHEAL (human amniotic membrane allograft); removed Biological: All sentinel cohort participants will receive biologic plus SOC. who receive at least one treatment of the biologic plus SOC and complete the treatment period of 12 weeks.·Standard wound care for diabetic foot ulcers·Biological: Participants in the randomized phase are assigned by randomization (2:1) to BIOxHEAL plus SOC or SOC alone. once weekly for up to 12 weeks or until complete ulcer closure
    + 4 other changes: index terms, verification date, description and design details
  2. Oct 1, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07852338
Lead sponsor
Applied Biologics, LLC
Responsible party
Sponsor
First posted
Oct 1, 2026
Start date
Oct 8, 2026 (estimated)
Primary completion
Sep 2027 (estimated)
Completion
Sep 2027 (estimated)
Last update
Oct 16, 2026

Study contacts

susan A weins, RN
Contact
susan.weins@appliedbiologics.com
2505142586
Charles Zelen, DPM
study director · Professional Education & Research Institute (PERI)

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion